

GeneDx is the leader in delivering clinical genomic answers to an ever-increasing community of patients, families and healthcare providers.
Explore Our Tests
"Without a doubt, the future of medicine will be personalized. Genetic and genomic testing that provides deeper insights into our health will play a key role in every stage of our lives moving forward — and we’re working hard to build that future."
Jane juusola, phd, facmg
– GeneDx Vice President, Medical Affairs
Senior Director, Clinical Genomics

Confidence comes from clear answers
GeneDx’s advanced genetic testing methods uncover complicated disease-causing DNA changes. Our unparalleled database, deep clinical knowledge, and mastery of variant interpretation allows us to turn data into diagnoses.
Rapid exome and genome sequencing
When timing is critical, a rapid diagnosis can shorten hospital stays, reduce healthcare costs and save lives.[1-5] Get verbal results with GenomeXpressTM, rapid genome sequencing, and XomeDxXpressⓇ, rapid exome sequencing, in 7 days.*
*The 7 day timeframe begins after both the patient’s and relative specimens, as appropriate, are received at our laboratory.

Repeat expansion analysis for ataxias
About 66% of ataxia cases have a genetic cause.[6,7] Our repeat expansion analysis tests can provide genetic confirmation to guide treatment decisions and help patients plan for the future.
How diagnostic genetic testing works

The healthcare provider gathers medical records and family history for review

The healthcare provider gathers medical records and family history for review

Healthcare provider orders test

A cheek swab, blood, or other specimen collected and sent to GeneDx

GeneDx takes DNA from the specimen, then sequences the DNA looking for changes in the patient's genome. The genetic data is analyzed and interpreted by our technical and clinical staff.

A report is sent to the healthcare provider with the test results

Here whenever you need us
MyGeneTeam, our preferred partner in genetic counseling services, helps you prepare for the genetic testing process and understand genetic results throughout every stage of the diagnostic journey.

Experience matters
For over 20 years, GeneDx has been at the forefront of genetic innovation, pioneering new technologies and gene discovery, enabling great diagnostic accuracy for patients and families.

Our team is on your side
At GeneDx, we collaborate with people and organizations involved in academic research, patient advocacy, and biopharma to search for new answers and increase access to clinical genetic testing for patients and their families. Through open communication and a mutual drive, we work with those who share our goal of building a better tomorrow.
- Soden SE, et al. “Effectiveness of exome and genome sequencing guided by acuity of illness for diagnosis of neurodevelopmental disorders.” Sci Transl Med 6(265):265ra168 (2014 Dec 3) doi.org/10.1038/gim.2017.1
- Stark Z et al. “A prospective evaluation of whole-exome sequencing as a first-tier molecular test in infants with suspected monogenic disorders.” Genet Med. 18(11):1090-1096 (2016 Nov) doi.org/10.1038/gim.2016.1
- Gubbels CS et al. “Prospective, phenotype-driven selection of critically ill neonates for rapid exome sequencing is associated with high diagnostic yield.” Genet Med. 22(4):736-744 (2020 Apr) doi.org/10.1038/s41436-019-0708-6
- Chung et al. “Rapid whole-exome sequencing facilitates precision medicine in paediatric rare disease patients and reduces health care costs.” The Lancet Regional Health-Western Pacific 1 (2020 Jul 24) doi.org/10.1016/j.lanwpc.2020.100001
- Wang H et al. “Clinical utility of 24-h rapid trio-exome sequencing for critically ill infants.” Npj Genomic Medicine 5(20) (2020 May 5) doi.org/10.1038/s41525-020-0129-0
- Fogel, Brent L et al. “Exome sequencing in the clinical diagnosis of sporadic or familial cerebellar ataxia.” JAMA neurology vol. 71,10 (2014): 1237-46. doi:10.1001/jamaneurol.2014.1944
- Németh, Andrea H et al. “Next-generation sequencing for molecular diagnosis of neurological disorders using ataxias as a model.” Brain: a journal of neurology vol. 136,Pt 10 (2013): 3106-18. doi:10.1093/brain/awt236